US 11,814,429 B2
Single domain antibodies to programmed cell death (PD-1)
Bryan Edwards, Cambridge (GB); Carolyn Edwards, Cambridge (GB); James Legg, Cambridge (GB); Martyna Lewandowska, Cambridge (GB); Daniela Sydoruk, Cambridge (GB); Colette Johnston, Cambridge (GB); Christine Rossant, Cambridge (GB); and Yumin Teng, Cambridge (GB)
Assigned to CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Appl. No. 16/475,590
Filed by CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
PCT Filed Jan. 8, 2018, PCT No. PCT/GB2018/050035
§ 371(c)(1), (2) Date Jul. 2, 2019,
PCT Pub. No. WO2018/127709, PCT Pub. Date Jul. 12, 2018.
Claims priority of application No. 1700207 (GB), filed on Jan. 6, 2017; application No. 1700208 (GB), filed on Jan. 6, 2017; and application No. 1700210 (GB), filed on Jan. 6, 2017.
Prior Publication US 2020/0239570 A1, Jul. 30, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); C12N 15/85 (2006.01); G01N 33/68 (2006.01); A61P 35/00 (2006.01); A01K 67/027 (2006.01)
CPC C07K 16/2818 (2013.01) [A01K 67/0278 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C12N 15/85 (2013.01); G01N 33/6803 (2013.01); A01K 2227/105 (2013.01); A61K 2039/505 (2013.01); C07K 16/18 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 10 Claims
 
1. An isolated single domain antibody that binds to human PD-1 but does not block the interaction of human PD-1 with human PD-L1 and/or PD-L2, wherein said single domain antibody is a human heavy chain variable domain (VH) comprising a CDR1, 2, and 3 having the following sequences SEQ ID NOs: 173, 174, and 175, respectively.